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Background and aims
CHEK2 gene is located on chromosome 22q12.1. and
encodes the human analogue of the yeast checkpoint
kinases Cds1 and Rad 53. Activation of CHEK2 in
response to DNA damage prevents the cell from enter-
ing into mitosis. Three founder alleles are present in
Poland. Two of these result in a truncated CHEK2 pro-
t e i nI V S 2 + 1 G > Ai ne x o n3a n d1 1 0 0d e lCi ne x o n1 0 ,
the other, I157T is a missense substitution of an isoleu-
cine for a threonine in exon 3. A single founder allele of
the CHEK2 has been associated with predisposition to
breast and prostate cancer in North America and Eur-
ope. CHK2 alterations are associated with an increased
risk of thyroid, prostate, breast, colon and kidney cancer
in Polish population. Recently, a large deletion of exons
9 and 10 of CHEK2 was identified in several unrelated
patients with breast cancer of Czech or Slovak origin,
the del 5395 also confers an increased risk of prostate
cancer in Polish men. The CHEK2 is therefore a good
candidate for a multisite cancer susceptibility gene. We
reasoned, that CHEK2 alterations ought to be investigate
in gastric cancer cases, too.
Patients and methods
We have examined the frequency of the CHEK2 gene
mutations in a series of randomized individuals includ-
ing 749 consecutively collected stomach cancer , 166
patients with familial gastric cancer, and 5496 control
patients. The 1100 del C, IVS2+1G®A, I 157 T and del
5395 mutations were identified by ASA-PCR, RFLP-
PCR, multiplex-PCR.
Results
The frequency of the I157T mutation in a group of con-
secutive gastric cancer patients was significantly elevated
compared to the control population (OR=1.418,
p=0.0348), herein in the group of patients diagnosed
with disease less then 50 years of age (OR=1.825,
p=0.0511). I157T was over-represented in the group of
familial gastric cancer patients (OR=2.246, p=0.003 )
too, herein in patients diagnosed with disease less then
50 years of age (OR=3.171, p=0.0044) and in females
(OR=2.973, p=0.0041).
The IVS2+1G>A was over-represented in a group of
consecutive patients with gastric cancers ( OR=3.367,
p=0.002), therein in patients diagnosed under 50 years
of age (OR=4.524, p=0.0377) and over 50 years of age
(OR=3.034, p=0.0183 ) additionally in males (OR=3.706,
p=0.0041). A large deletion of exons 9 and 10 confers
an increased risk of familial gastric cancer in patients
diagnosed over 50 years of age (OR=5.922, p=0.0598),
but this result is not quite significant.
Conclusions
The CHEK2 I157T mutation may be a predisposing
genetic factor associated with both, consecutive and
familial gastric cancer risk. Occurrence of IVS2+1G®A
alteration confers an increased risk of consecutive gas-
tric cancer.
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